Merck signs cancer research deal with AI drug discovery firm Isomorphic Labs
· 1 sources
Seeking Alpha reports that Merck has agreed a cancer research deal with Isomorphic Labs, a company focused on AI-based drug discovery.
What happened
Seeking Alpha reports that Merck has entered into a cancer research agreement with Isomorphic Labs, a firm that uses artificial intelligence in drug discovery.
The source describes the arrangement as a deal centered on cancer research. The headline does not provide financial terms, timelines or the specific programs involved.
Context
Large pharmaceutical companies often work with technology firms that apply artificial intelligence to the search for new drug candidates.
Why it matters
The agreement shows how Merck is drawing on AI-focused partners in its oncology research, which investors following the company may watch.
Stocks in this story
Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.
$137.78−3.90% vs. previous close ($143.37) · November 18
Fair value (ATLAS)
$61.72Fair range: $47.12 to $115.85The price ($137.78) is 123.3% above that figure.
Chance of a rise in 1 month
51%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $130.94 and $145.54; 9 in 10, between $119.23 and $159.83.
Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy